New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

  • The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
  • Researchers used Abbott's i-STAT™ TBI Plasma test – the only FDA-cleared rapid test on a portable analyzer for concussion – and Abbott's core laboratory ARCHITECT instrument to measure two biomarkers in blood plasma associated with brain injury

A new study published in The Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how someone will recover from traumatic brain injury (TBI). Testing for these two biomarkers in the immediate aftermath of an injury can help health care providers determine the best way to treat and care for patients.

This research shows that when a clinician conducts a blood test for these brain proteins soon after a possible injury, they quickly get a more accurate picture of how severe the injury is, the expected course of recovery and the longer-term implications of the TBI. The markers were measured using Abbott's i-STAT™ TBI Plasma test , as well as on the company's ARCHITECT core laboratory instrument using research prototype assays, both of which helped predict recovery.

Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury. After testing biomarker levels on the day of injury, researchers evaluated patients six months later, tracking how individuals fared and how biomarker levels corresponded to their recovery.

"Brain injury biomarkers will one day be the standard of care to evaluate and treat patients," said Dr. Fred Korley , an associate professor of emergency medicine at the University of Michigan and the first author of the study. "Objective biomarker data can be profoundly helpful in determining prognosis for a patient, helping to gauge how severe a brain injury is, and can ultimately inform how best to counsel family members about care for their loved ones with brain injury."

In the study, researchers examined the day-of-injury blood tests of 1,696 patients with TBI and compared those to patients' six-month assessment, using the Glasgow Outcome Scale Extended, which grades outcomes and quantifies levels of disability following TBI. The researchers found that high values of the biomarkers, GFAP and UCH-L1, correlate with death and severe injury. The day-of-injury blood tests had a high probability of predicting death at six months, 87% for GFAP and 89% for UCH-L1; and a high probability of predicting severe disability at the same timepoint, 86% for both GFAP and UCH-L1.

GFAP and UCH-L1 are proteins found in glial cells and neurons and are released into the blood stream after the brain is injured. They can be measured with diagnostic testing. Abbott's i-STAT TBI Plasma test is the first rapid test on a portable analyzer to receive FDA 510(k) clearance and can help determine the need for a computed tomography (CT) scan. Test results are available approximately 15 minutes after a plasma sample is inserted in the test i-STAT cartridge.

Abbott is pursuing FDA clearance under Breakthrough Designation for the TBI test on its Alinity i and ARCHITECT core laboratory instruments, which will broaden access and ensure that tests are available both in the lab and in other settings where people need immediate answers and care. Abbott's TBI test on Alinity i is CE Marked and available outside the U.S.

The subjects for the study came from the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study. TRACK-TBI collected and analyzed detailed clinical data from enrolled people across the injury spectrum at 18 U.S. level I trauma centers from February 2014 through August 2018 . The TRACK-TBI research team were among the first to demonstrate how this rapid TBI blood test can be used for the benefit of TBI patients in clinical care.

Abbott's TBI blood test was developed in collaboration with the U.S. Department of Defense (DoD) – which has been dedicated to developing a solution for the objective detection and evaluation of TBI for more than a decade. The DoD, through U.S. Army Medical Research and Development Command's (USAMRDC) U.S. Army Medical Materiel Development Activity (USAMMDA), played a critical role in developing the test run on Abbott's i-STAT TBI platform.

About i-STAT™ TBI Plasma

The i-STAT TBI Plasma test measures the level of biomarkers associated with brain injury in the blood stream to assist in determining the need for a CT scan of the head. The i-STAT TBI Plasma test is used to help evaluate mild TBI and is only available for use on the i-STAT Alinity instrument. The test is to be used with plasma prepared from EDTA anticoagulated specimens in clinical laboratory settings by a healthcare professional.  The i-STAT TBI Plasma test is not intended to be used in point-of-care settings. More information is available at www.globalpointofcare.abbott/en/product-details/apoc/istat-tbi-plasma.html

About i-STAT™ Alinity™

The i-STAT™ Alinity is an easy-to-use, portable blood analyzer that delivers real-time, lab-quality diagnostic test results. Health care professionals simply apply a few drops of blood into a cartridge, insert the cartridge into the analyzer and can view results within minutes. Results can then be transmitted wirelessly. More information is available at www.globalpointofcare.abbott/en/product-details/apoc/istat-alinity.html

About Abbott

Abbott (NYSE: ABT) is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Cision View original content: https://www.prnewswire.com/news-releases/new-study-shows-abbotts-blood-test-for-concussion-could-predict-outcomes-from-brain-injury-and-inform-treatment-interventions-301603905.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 “long haulers,” who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

Keep reading...Show less
abt stock

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 "long haulers," who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Aehr Test Systems Receives Orders of Over $2.3 million

Aehr Test Systems (NASDAQ:AEHR) has over 2,500 systems installed over the world that test optical and memory integrated circuits, semiconductors and reliability qualification equipment announced that it received over $2.3 million in orders for test and burn-in services. These orders came from a major manufacturer where Aehr’s services would be implemented for automotive products.

As quoted in the press release:

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CardieX Limited

Funding Commitment Agreement Update

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) provides an update on the Funding Commitment Agreement (FCA) with C2 Ventures Pty Limited (C2V, owned by Directors Niall Cairns and Craig Cooper) as announced on 8 November 2023.

Keep reading...Show less

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

  • New pharmacokinetic data demonstrate Virtue ® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 days of balloon delivery
  • AVIM therapy presentation highlighted recent clinical results showing favorable hemodynamic effects and long-term reduction in 24-hour ambulatory systolic blood pressure, as well as the design of the BACKBEAT global pivotal study now enrolling in collaboration with Medtronic, plc (NYSE:MDT)

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two oral presentations were given at the Cardiovascular Research Technologies ("CRT") 2024 Meeting in Washington, D.C. One presentation featured new preclinical pharmacokinetic ("PK") data on Virtue ® Sirolimus AngioInfusion Balloon ("SAB"), a novel drug-eluting balloon angioplasty system designed to deliver a proprietary, extended-release formulation of sirolimus, SirolimusEFR™ to the vessel wall during balloon angioplasty without any coating on the balloon surface. A second presentation featured recently reported clinical data on atrioventricular interval modulation ("AVIM") therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure. The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

New real-world data shows MiniMed 780G system sustains strong global performance, exceeding international targets for diabetes management

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures

Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States . The data was presented at the 17 th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy . These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for fourth quarter of fiscal year 2024

Board authorizes $5 billion for share repurchases

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 7, 2024 approved the company's cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in May 2023.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 consecutive years. The dividend is payable on April 12, 2024 to shareholders of record at the close of business on March 22, 2024 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×